Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Connect Biopharma Holdings Ltd Create: Alert

All | News | Filings
Date FiledTypeDescription
07/14/2023 6-K Quarterly results
06/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"INVESTOR CONTACT:"
03/21/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions March 17, 2023 ePoster and Oral Presentation at American Academy of Dermatology Annual Meeting",
"Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms March 18, 2023 Late-Breaking Abstract and Oral Presentation at American Academy of Dermatology Annual Meeting • Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints • No efficacy plateau at Week 16"
12/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"805.427.1372 [email protected] MEDIA"
12/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
10/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "805.427.1372 [email protected] Corporate Contacts: [email protected] 41"
08/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
08/19/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
07/11/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
06/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
06/10/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "2022 Jefferies Global Healthcare Conference Presentation",
"2022 Jefferies Global Healthcare Conference Presentation"
05/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/05/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/03/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis",
"Corporate presentation"
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update"
03/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
02/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "SVB Leerink 11th Annual Global Healthcare Conference Presentation",
"SVB Leerink 11th Annual Global Healthcare Conference Presentation"
01/05/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis",
"Corporate presentation"
11/22/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
11/19/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 - Connect Biopharma Holdings Limited , a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-307 in adult patients with moderate-to-severe Ulcerative Colitis . This global, randomized, double-blind, placebo-controlled phase 2 clinical trial is being conducted at multiple sites, including in the U.S., to evaluate the efficacy and safety of CBP-307 in 134 subjects, where CB..."
11/19/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis"
09/08/2021 6-K Quarterly results
09/02/2021 6-K Quarterly results
08/31/2021 6-K Quarterly results
08/27/2021 6-K Quarterly results
06/16/2021 6-K Quarterly results
06/03/2021 6-K Quarterly results
05/17/2021 6-K Quarterly results
05/11/2021 6-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy